Drug
Tenapanor
Tenapanor: highest development phase Post-Market, developed by Ardelyx. 16 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Ardelyx
Trials
| Drug | Phase | Indication |
|---|---|---|
| Tenapanor NCT05995899 | Post-Market | IBS |
| Tenapanor NCT03988920 | Post-Market | Hyperphosphatemia |
| Tenapanor NCT04549597 | Post-Market | Chronic Kidney Disease Requiring Chronic Dialysis |
| IBSRELA | Approved | |
| Tenapanor NCT03427125 | Phase 3 | Hyperphosphatemia |
| Tenapanor 50 MG NCT05643534 | Phase 3 | Irritable Bowel Syndrome With Constipation (IBS-C) |
| Tenapanor NCT02727751 | Phase 3 | Constipation Predominant Irritable Bowel Syndrome |
| Tenapanor NCT02621892 | Phase 3 | Constipation Predominant Irritable Bowel Syndrome |
| Tenapanor NCT05905926 | Phase 3 | Irritable Bowel Syndrome With Constipation (IBS-C) |
| Tenapanor NCT02675998 | Phase 3 | Hyperphosphatemia |
| Tenapanor NCT06810167 | Phase 3 | Cystic Fibrosis |
| Tenapanor NCT02686138 | Phase 3 | Constipation Predominant Irritable Bowel Syndrome |
| Tenapanor NCT03824587 | Phase 2/3 | Hyperphosphatemia |
| Tenapanor NCT06460038 | Phase 2 | Synucleinopathy |
| Tenapanor NCT06553547 | Phase 2 | Irritable Bowel Syndrome With Constipation (IBS-C) |
| Tenapanor NCT06203444 | Phase 1 | Lactation |
Latest
No recent events.
Follow Tenapanor on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.